Skip to main content

PRESS RELEASES

Date Title  
06/12/19
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 12, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, today
05/29/19
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 29, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that it will present at the Jefferies 2019 Healthcare Conference in New York, NY on Wednesday, June 5 th at 2:30 p.m. ET . A live audio webcast of the presentation will be available under the
05/02/19
- Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs – - SER-287 Fast Track designation obtained for active mild-to-moderate ulcerative colitis; Phase 2b study enrollment expected to be completed by mid-2020 and top-line
04/29/19
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 29, 2019-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on May 2, 2019 at 8:30 a.m. ET to discuss first quarter 2019 results and provide a general business update.
04/02/19
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 2, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that new preclinical data supporting the development of microbiome therapeutics for immuno-oncology (poster title “Leveraging gut microbiota networks to impact tumor immunotherapy”) 1 will be
03/11/19
- Collaboration focused on further elucidating the potential of microbiome therapeutics to augment immuno-oncology treatment for cancer – - Seres to receive $20 million and financial support for research activities – - Company to further discuss collaboration during webcast Cowen healthcare
03/06/19
- Initiated SER-287 Phase 2b study in mild-to-moderate ulcerative colitis - - Initiated SER-401 Phase 1b study in metastatic melanoma - - Conference call at 8:30 a.m. ET today - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 6, 2019-- Seres Therapeutics, Inc.
03/05/19
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that it will present at each of the following upcoming healthcare conferences: Chardan’s Inaugural Microbiome Summit : a corporate overview will be presented on Thursday, March 7 th at 8:10
03/04/19
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 4, 2019-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on March 6, 2019 at 8:30 a.m. ET to discuss fourth quarter and full year 2018 results and provide a general business update.
02/07/19
- Focusing resources on clinical readouts from late-stage microbiome programs for ulcerative colitis, C. difficile infection and planned immuno-oncology study - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 7, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced certain corporate changes to

Back to top